ADVENTRX Pharmaceuticals announces 6-month stability data for Exelbine ADVENTRX Pharmaceuticals, Inc. The 6-month balance data are on the right track to support the submission of the New Drug Software for Exelbine. Culley, Chief Executive Officer of ADVENTRX. Once we have the 12-month data, we will submit the Exelbine NDA, which we expect will take place in the 4th quarter of this year. .‘Previous studies that suggested protein was beneficial used ‘ride to exhaustion’ tests that do not resemble regular athletic competition. Furthermore, the topics in those research received less than the perfect recommended amount of carbohydrate,’ says Gibala. ‘Our research demonstrates protein confers no efficiency benefit during ‘real life’ exercise when sportsmen consume sufficient levels of a sports beverage.’ The study, which was funded by Gatorade, comes at the same time when the sports drink market is under great pressure to create new products by adding ingredients that might further enhance functionality.